Niagen Bioscience Expands IP Portfolio with New U.S. Patent for IV and Injectable NR Formulations

Event summary

  • Niagen Bioscience secured U.S. Patent No. 12,558,367 covering intravenous and injectable formulations of nicotinamide riboside (NR).
  • The patent extends protection through 2044 and includes claims for aqueous formulations, multiple administration routes, and combination use with other NAD+ precursors.
  • Niagen IV is available at over 1,200 healthcare, wellness, and longevity clinics across the U.S.
  • The company's patent portfolio now includes over 100 patents covering its flagship Niagen ingredient and other NAD+ precursors.

The big picture

Niagen Bioscience's new patent strengthens its position in the burgeoning healthy aging market, particularly in the IV and injectable NAD+ precursor segment. The patent's broad claims and long-term protection (through 2044) reinforce the company's ability to defend its market share and explore new commercial opportunities. This move aligns with the broader industry trend of leveraging intellectual property to secure competitive advantages in the rapidly growing longevity and healthy aging sectors.

What we're watching

IP Strategy
How Niagen Bioscience will leverage this patent to expand its commercial pathways and partnerships in the healthy aging category.
Market Penetration
The pace at which Niagen IV adoption will grow across the 1,200 U.S. clinics and whether it can sustain market leadership.
Regulatory Compliance
Whether Niagen Bioscience can maintain its position on the U.S. FDA Bulk Drug Substances Nominated for Use in Compounding Under Section 503B list.

Related topics

Biotechnology